A new study published in The Lancet Gastroenterology and Hepatology revealed that individuals with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD) undergo significantly higher risks of severe liver complications when compared to those with metabolic dysfunction-associated steatotic liver disease (MASLD).

This research systematically analyzed 24 cohort studies encompassing more than 11.5 million adults throughout the globe. Of these, approximately 9.8 million had MASLD, while 1.7 million had MetALD. The participants with MASLD were on average older (57 years vs. 49 years) and included a larger proportion of women (38% vs. 18%) when compared to the individuals with MetALD, where men predominated.

This study assessed risks for a range of outcomes, including l

See Full Page